ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/haematology/myeloproliferative-neoplasms
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Myeloproliferative neoplasms
36
trial(s) found.
NCT07849231
Haem
Phase 1
Recruiting
A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies, Administered Alone or in Combination With Ruxolitinib, in Participants With CALR-mutant Myeloproliferative Neoplasms (
CLARITY-101
)
JAK1/JAK2 inhibitor
Myeloproliferative Neoplasm
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT07623200
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (
EXCALIBUR-ET2
)
anti-CALR monoclonal antibody
Essential thrombocythaemia
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
6168 - Cooloongup - Rockingham Hospital
NCT07623161
Haem
Phase 3
Recruiting
A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept (TAK-226) Compared to Placebo in Participants With Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy (
ELRISE-MF
)
JAK1/JAK2 inhibitor
modified ActRIIA ligand trap protein
placebo
Myelofibrosis
NSW
2217 - Kogarah - St George Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT07612280
Haem
Phase 1 / Phase 2
Recruiting
Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis (
JBI-802-102
)
LSD1/HDAC6 inhibitor
Essential thrombocythaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
Myeloproliferative Neoplasm
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - Hollywood Private Hospital
NCT07469891
Haem
Phase 1
Recruiting
A Phase 1, Open-Label, Multi-Center, Safety and Efficacy Study of PRT12396 in Participants With Polycythemia Vera and Myelofibrosis (
PRT12396-01
)
JAK2 inhibitor,JH2 domain selective
Essential thrombocythaemia
Myelofibrosis
Myeloproliferative Neoplasm
Polycythemia vera
VIC
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT07441694
Haem
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms (
INCA036978-101
)
unknown drug class
Myeloproliferative Neoplasm
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT07429266
Haem
Phase 3
Recruiting
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera (
INTREPID
)
antisense oligonucleotide therapy,TMPRSS6-targeting
placebo
Polycythemia vera
WA
6005 - West Perth - Perth Blood Institute
NCT07422480
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-na\xEFve Adult Participants Who Require Red Blood Cell Transfusions (
ELRiSE-MDS
)
erythropoiesis stimulating agent
modified ActRIIA ligand trap protein
Myelodysplastic syndrome
NSW
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3181 - Prahran - The Alfred Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07357727
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Active-control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients With Myelofibrosis Who Are JAK Inhibitor Naive (
MANIFEST-3
)
BET inhibitor
JAK1/JAK2 inhibitor
placebo
Essential thrombocythaemia
Myelofibrosis
Polycythaemia vera
VIC
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07155226
Haem
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression (
MOMENTUM
)
menin-MLL1 inhibitor
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6000 - Perth - Royal Perth Hospital
NCT07008118
Haem
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms (
INCA035784-101
)
bispecific T-cell engager,CALR-targeting
Myeloproliferative Neoplasm
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06788509
Haem
Phase 1
Enrolling by invitation
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring (
PLATFORMPACAN1001
)
BTK inhibitor
Ibrutinib
JNJ-80948543
MALT1 inhibitor
Rezetamig
Safimaltib
bispecific T-cell engager,CD22-targeting
cancer therapy
cancer therapy,BTK-targeting
cancer therapy,CD20-targeting
cancer therapy,CD22-targeting
cancer therapy,CD79b-targeting
cancer therapy,MALT1-targeting
immuno-oncology therapy,CD20-targeting
immuno-oncology therapy,CD22-targeting
immuno-oncology therapy,CD79b-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
trispecific CD79b/CD20/CD3 antibody
Cancer
Castrate-resistant prostate cancer
Leukaemia
Lymphoma
Myelodysplastic syndrome
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Linear Clinical Research
NCT06656494
Haem
Phase 1
Recruiting
A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies. (
ICP-CL-01205
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Leukaemia
Myelodysplastic syndrome
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT06641414
Haem
Phase 3
Recruiting
A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4). (
APG2575MG301
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Myelodysplastic syndrome
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Icon Cancer Centre Richmond
WA
6000 - Perth - Royal Perth Hospital
6168 - Cooloongup - Rockingham Hospital
NCT06499285
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW) (
KER-050-D301
)
modified ActRIIA ligand trap protein
placebo
Myelodysplastic syndrome
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT06479135
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Na\xEFve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (
POIESIS
)
JAK1/JAK2 inhibitor
MDM2 inhibitor
placebo
Myelofibrosis
NSW
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06465953
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (
PyramIDH
Study)
DNA methyltransferase inhibitor
IDH1 R132 inhibitor
antimetabolite
Myelodysplastic syndrome
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06372717
Haem
Phase 1
Recruiting
A Phase 1 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and in Combination With Azacitidine and in Combination With Azacitidine Plus Venetoclax in Adults With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB) (
AP30CP01
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
multikinase inhibitor,integrated stress response-targeting
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Hollywood Private Hospital
NCT06351631
Haem
Phase 3
Recruiting
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study (
3543-017
)
LSD1 inhibitor
Myelofibrosis
Polycythemia vera
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05636514
Haem
Phase 1
Recruiting
A Phase I Study of Oral Decitabine and Cedazuridine (ASTX727) In Combination With Defactinib (VS-6063) as Therapy of Myelodysplastic Syndromes and Low-blast Acute Myeloid Leukaemia (
CELESTIAL-MDS
)
DNA methyltransferase inhibitor
FAK inhibitor
cytidine deaminase inhibitor
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
Myelodysplastic syndrome
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
NCT05320198
Haem
Phase 1 / Phase 2
Recruiting
RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia (
DISC-0974-102
)
anti-hemojuvelin monoclonal antibody
Myelodysplastic syndrome
Myelofibrosis
Polycythaemia vera
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3021 - St Albans - Western Health - Sunshine Hospital
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - Linear Clinical Research
NCT05269771
Paed
No longer available
Treatment Plan for Managed Access Program (MAP) to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera (PV) (
CINC424B2002I
)
JAK1/JAK2 inhibitor
Polycythemia vera
NSW
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
NCT05037760
Haem
Phase 2
Recruiting
A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis (
KER050-MF-301
)
JAK1/JAK2 inhibitor
modified ActRIIA ligand trap protein
Myelofibrosis
NSW
2139 - Concord - Concord Repatriation General Hospital
2485 - Tweed Heads - The Tweed Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
SA
5042 - Bedford Park - Flinders Medical Centre
NCT04771130
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
BGB-11417-103
)
Bcl2 inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6009 - Nedlands - One Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04581512
Haem
Phase 1 / Phase 2
Recruiting
A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies (
EP0042-101
)
FLT3/Aurora inhibitor
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
Myelodysplastic syndrome
WA
6000 - Perth - Royal Perth Hospital
NCT04419649
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (
KER050-MD-201
)
modified ActRIIA ligand trap protein
Myelodysplastic syndrome
NA
2025 - Papatoetoe - Middlemore Hospital
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT04176198
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis (
BBI-TP-3654-102
)
PIM1 kinase inhibitor,selective
Myelofibrosis
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT04064060
Haem
Phase 3
Recruiting
A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials (
ACE-536-LTFU-001
)
recombinant human ActRIIb fusion protein
Myelodysplastic syndrome
Myelofibrosis
NOT Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT03850574
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (
TUSCANY
)
FLT3 inhibitor
Chronic myelomonocytic leukaemia
Leukaemia
Myelodysplastic syndrome
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4812 - Townsville - Townsville University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12626000638336
Haem
Phase 1
Not yet recruiting
A Dose finding Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ZE74-0282 in Select JAK2 V617F Mutated Hematologic Disorders (
ZE74-0282-0002
)
JAK2 inhibitor,JH2 domain selective
Myeloproliferative Neoplasm
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12626000019303
Haem
Phase 2
Not yet recruiting
A Double-blind, Phase I/II, Randomised Study to Compare the Efficacy of Enzomenib Versus Placebo as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation in Subjects with Acute Myeloid Leukaemia (AML). (
ACT-MIM-001
)
menin inhibitor
placebo
Acute myeloid leukaemia
Cancer
Myelodysplastic syndrome
ACTRN12622001302741
Haem
Phase 1 / Phase 2
Not yet recruiting
MDS05/D2 - A multicentre phase Ib/II open label randomized platform design study to determine the safety and efficacy of SRA515 and ASTX727 for treatment of intermediate and high risk Myelodysplastic Syndrome (MDS). (
ALLG
)
BRD4 inhibitor
cytidine deaminase inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
ACTRN12622001232729
Radonc
Phase 2
Recruiting
A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (
The-ANZHIT-2-study
)
Cyclophosphamide
Fludarabine
Mesna
Radiotherapy
Tacrolimus
Treosulfan
alkylating agent
antimetabolite
calcineurin inhibitor
cancer therapy
cytotoxic chemotherapy
sodium mercaptoethanesulfonate
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Chronic myelogenous leukaemia
Myelodysplastic syndrome
Myeloproliferative Neoplasm
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12622000308796
Haem
Phase 1
Recruiting
A phase 1 study to assess the safety of short-course treatment with venetoclax prior to non-myeloablative stem cell transplantation for patients with haematological malignancies. (
VICTORY-study
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Leukaemia
Lymphoma
Multiple myeloma
Myelodysplastic syndrome
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
ACTRN12611000364976
Haem
Phase 1
Not yet recruiting
Pharmacokinetics and Safety of Solid Oral Posaconazole (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1b; Protocol No. P05615) (
NIL
)
azole antifungal
Leukaemia
Myelodysplastic syndrome
ACTRN12610000641099
Haem
Phase 2
Recruiting
A single arm pilot study of azacitidine in myelodysplastic syndrome / acute myeloid leukaemia, with eltrombopag support for thrombocytopenia (
AZA-E
)
DNA methyltransferase inhibitor
antimetabolite
thrombopoietin receptor agonist
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (30)
Not yet recruiting (4)
Enrolling by invitation (1)
No longer available (1)
Recruitment Country and State
VIC (26)
NSW (23)
WA (20)
SA (15)
QLD (10)
NZ (4)
ACT (2)
TAS (1)
Phase
Phase 1 (11)
Phase 1 / Phase 2 (8)
Phase 2 (5)
Phase 3 (11)
Trial Type
Haem (34)
Paed (1)
Radonc (1)
Cancer Therapy Class
DNA methyltransferase
28%
JAK1
19%
JAK2
19%
Bcl2
19%
CALR
6%
LSD1
6%
menin
6%
cytidine deaminase
6%
FLT3
6%
HDAC6
3%
BET
3%
KMT2A
3%
menin-MLL1
3%
BTK
3%
CD20
3%
CD22
3%
CD79b
3%
MALT1
3%
MDM2
3%
IDH1
3%
IDH1 R132
3%
ISR
3%
multikinase
3%
FAK
3%
AURKA
3%
AURKB
3%
Aurora
3%
BRD4
3%
Facility
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (13)
3168 - Clayton - Monash Medical Centre (11)
3065 - Fitzroy - St Vincent's Hospital Melbourne (10)
3004 - Melbourne, Southbank - Alfred Health (9)
6000 - Perth - Royal Perth Hospital (7)
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
5042 - Bedford Park - Flinders Medical Centre (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
2170 - Liverpool - Liverpool Hospital (4)
3128 - Box Hill - Box Hill Hospital - Eastern Health (4)
2217 - Kogarah - St George Hospital (4)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (4)
2139 - Concord - Concord Repatriation General Hospital (4)
6009 - Nedlands - Linear Clinical Research (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
2109 - North Ryde - Macquarie University Hospital (3)
6005 - West Perth - Perth Blood Institute (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (3)
2031 - Randwick - Prince of Wales Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
2605 - Garran - The Canberra Hospital (2)
6168 - Cooloongup - Rockingham Hospital (2)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (2)
6009 - Nedlands - Hollywood Private Hospital (2)
6009 - Nedlands - One Clinical Research (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
3066 - Epping - Northern Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
NZ.0622 - Takapuna - North Shore Hospital (2)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (2)
2485 - Tweed Heads - The Tweed Hospital (2)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
4575 - Birtinya - Sunshine Coast University Hospital (1)
2487 - Cudgen - Tweed Valley Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
3181 - Prahran - The Alfred Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3121 - Richmond - Icon Cancer Centre Richmond (1)
7000 - Hobart - Royal Hobart Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
2025 - Papatoetoe - Middlemore Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
4812 - Townsville - Townsville University Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
Cancer Type
Cancer
Haematological malignancy
Myeloproliferative neoplasm
Myelodysplastic syndrome
Leukaemia
Myelofibrosis
Acute myeloid leukaemia
Myeloid leukaemia
Polycythaemia vera
Myelodysplastic/Myeloproliferative disease
Essential thrombocythaemia
Lymphoid leukaemia
Chronic myelomonocytic leukaemia
Acute lymphoblastic leukaemia
Lymphoma
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Solid tumour
Urogenital cancer
Chronic leukaemia
Chronic myelogenous leukaemia
B-cell malignancy
Chronic lymphocytic leukaemia
Mature B-cell malignancy
Multiple myeloma
Non-Hodgkin's lymphoma
Plasma cell disorder
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy